3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
6
Leukemia, Myeloid, Acute
3
Carcinoma, Renal Cell
3
Ovarian Cancer Metastatic
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Kidney Neoplasms
1
Invasive Bladder Cancer Stage IV
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
6
Radiotherapy
5
Carboplatin
5
capmatinib
2
Radiosurgery
2
Gemcitabine
2
tetrathiomolybdate
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
onartuzumab
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
efaproxiral
1
durvalumab
1
binimetinib
1
aldesleukin
1
Vinorelbine
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sorafenib
1
Platinum
1
Nivolumab
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gefitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma of Lung
×
Interleukin-2
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn